A phase I trial of lenalidomide in patients with recurrent primary central nervous system tumors.
about
Mechanism of action of lenalidomide in hematological malignanciesClinical Pharmacokinetics and Pharmacodynamics of Lenalidomide.Phase I study of oral lenalidomide in patients with refractory metastatic cancerProgress on antiangiogenic therapy for patients with malignant glioma.Thalidomide-a notorious sedative to a wonder anticancer drug.Safety, pharmacokinetics, and immunomodulatory effects of lenalidomide in children and adolescents with relapsed/refractory solid tumors or myelodysplastic syndrome: a Children's Oncology Group Phase I Consortium report.Phase I trial of lenalidomide in pediatric patients with recurrent, refractory, or progressive primary CNS tumors: Pediatric Brain Tumor Consortium study PBTC-018.Phase I trial of lenalidomide and CCI-779 in patients with relapsed multiple myeloma: evidence for lenalidomide-CCI-779 interaction via P-glycoproteinPharmacokinetics and tissue disposition of lenalidomide in mice.The combination of novel targeted molecular agents and radiation in the treatment of pediatric gliomas.Plasma and cerebrospinal fluid pharmacokinetics of thalidomide and lenalidomide in nonhuman primates.Antiangiogenic therapy in brain tumors.A phase II trial of thalidomide and procarbazine in adult patients with recurrent or progressive malignant gliomas.Lenalidomide Polarizes Th1-specific Anti-tumor Immune Response and Expands XBP1 Antigen-Specific Central Memory CD3(+)CD8(+) T cells against Various Solid Tumors.Antiangiogenic strategies for treatment of malignant gliomas.Targeted therapy in the treatment of malignant gliomasLenalidomide: a synthetic compound with an evolving role in cancer management.Anti-angiogenic therapy in glioma.Lenalidomide in solid tumors.Antiangiogenic therapy for high-grade gliomas: current concepts and limitations.Targeted therapy in gliomas.A Single Institution's Experience with Bevacizumab in Combination with Cytotoxic Chemotherapy in Progressive Malignant Glioma.New Directions in Anti-Angiogenic Therapy for Glioblastoma.Efficacy against subcutaneous or intracranial murine GL261 gliomas in relation to the concentration of the vascular-disrupting agent, 5,6-dimethylxanthenone-4-acetic acid (DMXAA), in the brain and plasma.Antiangiogenic therapy for patients with recurrent and newly diagnosed malignant gliomas.Trial Watch: Lenalidomide-based immunochemotherapy.Evidence and Context of Use for Contrast Enhancement as a Surrogate of Disease Burden and Treatment Response in Malignant Glioma.
P2860
Q21198872-94F1E96F-0ABB-46FF-8330-03E5144991E7Q33433453-34FE9ABD-3239-43D5-8416-F1250505710BQ33600521-5B4894A1-8F06-444B-9C3D-BE7583CE1AD2Q33773189-F033365C-AD15-4CEA-93E4-C3C80C9C55C7Q33956871-B82D3F17-C6C0-47E0-9612-A498234E13BFQ34666858-03FDC12C-B183-41B9-A54F-D1C636F86DEDQ34666866-214B6480-4531-4AC3-B431-CA8FB41844E6Q35187824-2C668945-1F89-4F82-8EB7-93CF7F90BE9CQ36331493-08975D27-B7F1-439E-A13C-DE90B235659AQ36833480-428EE728-42C2-409F-8492-742A78FE1ED7Q36936541-C0E6F588-2E96-46A0-8386-8B042A79A5D1Q37129915-DEBE0FC3-BC15-4717-B1BB-7B489EE0D1A0Q37192227-31EB03D5-261F-400D-B5FE-2354A4696C85Q37275289-1B3695C0-AB8F-4B26-B4EA-368753C19296Q37533652-E8B89B57-C93E-413F-A57E-19B4E970F40FQ37771247-1D5DFB74-48B4-45FA-A078-38AB6045BFF4Q37791617-8B436776-6C45-45F7-97A3-24B943F7E94CQ37877409-191C6C74-A4D6-462D-A435-4EB402334520Q38010055-4CD9AC80-4C8F-44E4-B6DD-4609FEA591C0Q38157034-6DEB9731-A583-4401-83C4-DD49A9AA70E1Q38186656-2224DFFC-7318-44E9-8CE4-3AAFB18FCC51Q38260841-7933E302-3BDA-495C-9B62-252AB82DC998Q39022941-691D0501-FA76-46B8-AE45-405A6D34F226Q39029184-664FF5C1-EF38-4A17-8B01-FFF1371F9E32Q42143173-19C4AB3B-2796-4DAD-9C14-0B15D451752EQ42737828-90241735-DD93-4FD8-BDEE-3B031C342429Q47436703-14F03A8E-AF5D-4969-9A24-05C2CFCE350A
P2860
A phase I trial of lenalidomide in patients with recurrent primary central nervous system tumors.
description
2007 nî lūn-bûn
@nan
2007年の論文
@ja
2007年学术文章
@wuu
2007年学术文章
@zh
2007年学术文章
@zh-cn
2007年学术文章
@zh-hans
2007年学术文章
@zh-my
2007年学术文章
@zh-sg
2007年學術文章
@yue
2007年學術文章
@zh-hant
name
A phase I trial of lenalidomid ...... central nervous system tumors.
@en
A phase I trial of lenalidomid ...... central nervous system tumors.
@nl
type
label
A phase I trial of lenalidomid ...... central nervous system tumors.
@en
A phase I trial of lenalidomid ...... central nervous system tumors.
@nl
prefLabel
A phase I trial of lenalidomid ...... central nervous system tumors.
@en
A phase I trial of lenalidomid ...... central nervous system tumors.
@nl
P2093
P1476
A phase I trial of lenalidomid ...... central nervous system tumors.
@en
P2093
Cheryl Royce
Howard A Fine
J Paul Duic
Lyndon Kim
Paul S Albert
Tanyifor Tohnya
William D Figg
P304
P356
10.1158/1078-0432.CCR-07-1546
P407
P577
2007-12-01T00:00:00Z